Zymeworks Inc.
ZYME
Rank in Stocks
#5565
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase,... Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
Share Price
$30.81
Last synced: 2026-11-09
Market Cap
$2.22B
Change (1 day)
3.98%
Change (1 year)
56.55%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Zymeworks Inc. (ZYME)
Category
Healthcare
Operating Margin for Zymeworks Inc. (ZYME)
Operating Margin as of November 2026 TTM: -418.99%
According to Zymeworks Inc.'s latest financial reports, its current operating margin (TTM) is -418.99%. At the end of 2025 the company had an operating margin of -87.33%.
Operating Margin history for Zymeworks Inc. from 2014 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -418.99% | 379.78% |
| 2025 | -87.33% | -51.40% |
| 2024 | -179.69% | -1.06% |
| 2023 | -181.62% | -674.02% |
| 2022 | 31.64% | -103.91% |
| 2021 | -808.22% | 67.93% |
| 2020 | -481.29% | -6.02% |
| 2019 | -512.12% | 719.65% |
| 2018 | -62.48% | 259.49% |
| 2017 | -17.38% | -94.95% |
| 2016 | -343.94% | 66.45% |
| 2015 | -206.63% | -72.93% |
| 2014 | -763.35% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.09% |
US
|
|
| -149.01% | -99.64% |
US
|
|
| 25.57% | -100.06% |
AU
|
|
| 31.23% | -100.07% |
BE
|
|
| 29.35% | -100.07% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Zymeworks Inc.'s operating margin
What is Zymeworks Inc.'s operating margin?
Zymeworks Inc.'s operating margin is -418.99%, as of Nov 2026.
What was Zymeworks Inc.'s operating margin in 2025?
In 2025, Zymeworks Inc.'s operating margin was -87.33%, compared with -179.69% in 2024.
How has Zymeworks Inc.'s operating margin changed since 2020?
From 2020 to 2025, Zymeworks Inc.'s operating margin was highest in 2022 (31.64%) and lowest in 2021 (-808.22%).
How does Zymeworks Inc.'s operating margin compare with similar companies?
Zymeworks Inc.'s operating margin (-418.99%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.